ICU Medical Announces First Quarter 2026 Results

About this update from Icu Medical, Inc.

[{"type":"image","alt":"ICU Medical, Inc.","displaySize":"","headline":null,"caption":"ICU Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":228,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/f1b81ec991808b15ae2c7684bd67adbe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f1PwaupCrMVq3dCiS1gXbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOA--/https://media.zenfs.com/en/globenewswire.com/f1b81ec991808b15ae2c7684bd67adbe","width":228,"height":75},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/f1PwaupCrMVq3dCiS1gXbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOA--/https://media.zenfs.com/en/globenewswire.com/f1b81ec991808b15ae2c7684bd67adbe","width":228,"height":75}},"lazy":false},{"type":"text","content":"SAN CLEMENTE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2026.","length":250,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Results","length":26,"tagName":"p"},{"type":"text","content":"The following year-over-year results reflect the strategic divestiture of the IV Solutions business on May 1, 2025. First quarter 2026 GAAP revenue declined 12% year-over-year; however, excluding the impact of the IV Solutions divestiture and foreign currency, non-GAAP organic revenue increased 1%.","length":299,"tagName":"p"},{"type":"text","content":"First quarter 2026 GAAP revenue was $530.2 million, as compared to $604.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2026 was $206.2 million, as compared to $210.1 million in the same period in the prior year. GAAP gross margin for the first quarter of 2026 was 39%, as compared to 35% in the same period in the prior year. GAAP net income for the first quarter of 2026 was $30.1 million, or $1.20 per diluted share, as compared to GAAP net loss of $(15.5) million, or $(0.63) per diluted share, for the first quarter of 2025. Adjusted diluted earnings per share for the first quarter of 2026 was $1.97 as compared to $1.72 for the first quarter of 2025. Adjusted EBITDA was $98.7 million for the first quarter of 2026 as compared to $99.4 million for the first quarter of 2025.","length":824,"tagName":"p"},{"type":"text","content":"Adjusted...

More updates from Icu Medical, Inc.